Phoenix Biotech Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Phoenix Biotech Acquisition (PBAXU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Phoenix Biotech Acquisition's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - | - | Yes |
| Competitors combined (65) | ||||
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PBAXU Stock Performance relative to its Competitors
PBAXU Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Century Therapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Phoenix Biotech Acquisition's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Phoenix Biotech Acquisition's Comment on Competition and Industry Peers
Publicly Traded Peers of Phoenix Biotech Acquisition Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Phoenix Biotech Acquisition Corp | 437.35 | - |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Gsk Plc | 102,307.45 | 32,667.00 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| SUBTOTAL | 1,022,533.93 | 155,769.17 |
Sign in to see all competitors of Phoenix Biotech Acquisition Corp.
Sources: Phoenix Biotech Acquisition Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Phoenix Biotech Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Phoenix Biotech Acquisition's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Adaptimmune Therapeutics, plc | Named by the company | 85% |
| TCR2 Therapeutics Inc. | Named by the company | 85% |
| TScan Therapeutics Inc. | Named by the company | 85% |
| GlaxoSmithKline plc | Named by the company | 85% |
| Immatics, N.V. | Named by the company | 85% |
| Adaptive Therapeutics, Inc. | Named by the company | 85% |
| 3T Biosciences, Inc. | Named by the company | 85% |
| MediGene AG | Named by the company | 85% |
| Ziopharm Oncology, Inc. | Named by the company | 85% |
| Gilead Sciences Inc | Named by the company | 85% |
| Amgen Inc | Named by the company | 85% |
| Nkarta Inc | Named by the company | 85% |
| Fate Therapeutics Inc | Named by the company | 85% |
| Allogene Therapeutics Inc | Named by the company | 85% |
| Century Therapeutics inc | Named by the company | 85% |
| Sana Biotechnology Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Phoenix Biotech Acquisition's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Phoenix Biotech Acquisition's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Illumina Inc | Sequencing 90.94 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | 437 | - | - |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Gsk Plc | 102,307 | 128,610,236 | 24,759,843 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| PEERS TOTAL | 1,022,097 | 2,119,164 | 185,064 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Illumina Inc | United States and Canada 56.34 % |
| Exelixis Inc | United States 91.44 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Phoenix Biotech Acquisition's industry classification, broader than the peer set above. Market cap in millions of $.Phoenix Biotech Acquisition ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,326, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,463 | 25.80 % |
| 2 | Gilead Sciences Inc | 189,197 | 21.46 % |
| 3 | Moderna Inc | 78,517 | 8.91 % |
| 4 | Argenx Se | 64,197 | 7.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Phoenix Biotech Acquisition Corp | 298 | 0.00 % |
Market cap and industry share for the rest of Phoenix Biotech Acquisition's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2024-02-07.
Phoenix Biotech Acquisition's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -2.26 % | 152.04 % | - |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Phoenix Biotech Acquisition's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,326 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Phoenix Biotech Acquisition's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Phoenix Biotech Acquisition's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Phoenix Biotech Acquisition's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 363.1 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (56.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Phoenix Biotech Acquisition's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | 0.04 | 0.14 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Gsk Plc | - | - | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Phoenix Biotech Acquisition's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| PEERS TOTAL | +6.5 % | - |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Phoenix Biotech Acquisition's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Phoenix Biotech Acquisition's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Phoenix Biotech Acquisition Corp | - | - |
| Amgen Inc | 25.97 | 5.97 |
| Gilead Sciences Inc | - | 6.21 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Gsk Plc | 17.90 | 3.13 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| PEERS AVERAGE | 75.42 | 6.56 |
Sign in to see all peers for Phoenix Biotech Acquisition Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.